Latest Cell Transplantation Stories
Pancreatic islet transplantation is a promising therapy for treating type 1 diabetes, but the majority of transplanted cells die soon after they are transplanted.
A research team in Spain has developed high-yield preparations of viable hepatocytes (liver cells) isolated for transplantation from cryopreserved (frozen), banked neonatal livers that ranged in age from one day to 23 days.
Autologous (self-donated) mononuclear cells derived from bone marrow (BMMNCs) have been found to significantly induce vascular growth when transplanted into patients with diabetes who are suffering from critical limb ischemia caused by peripheral artery disease (PAD), a complication of diabetes.
Researchers in Japan have completed a study showing that stem cells derived from deciduous canine teeth and dental pulp can be grafted and produce bone regeneration between parents and offspring.
Transplanting human umbilical cord blood-derived endothelial progenitor cells (EPCs) has been found to "significantly accelerate" wound closure in diabetic mouse models.
Two studies published in the current issue of Cell Transplantation (19:12) investigate frontiers of islet cell transplantation for treating diabetes. Researchers in Milan, Italy re-examine the role of bone marrow stem cells in diabetic therapy and islet cell regeneration and Canadian researchers offer improved strategies for optimizing pancreatic islet culture in vitro.
Transplanting their own (autologous) bone marrow-derived stem cells into 48 patients with end-stage liver disease resulted in therapeutic benefit to a high number of the patients.
A team of researchers from several collaborating Baylor University research centers and from Japan's Okayama Graduate School of Medicine have found a way to more consistently isolate pancreatic islet cells from brain dead donors using ductal injection (DI), a process that immediately cools donor islet cells at the injection site.
A study published in the current issue of Cell Transplantation (19:1) has found that using the FDA-approved contrast agent Indocyanine Green (ICG) to label human embryonic stem cell-derived cardiomyocytes (hESC-CMs) substantially improved efforts to optically track stem cells after transplanting them into heart tissues.
Two studies published in the latest issue of Cell Transplantation (18:12) may lead to new treatments for the treatment of heart diseases.
- Large; stout; burly.